We harness atomic resolution comparative structural data to meticulously engineer Pathogen-Specific cytotoxic agents.
At ASTRA Therapeutics, we are dedicated to discovering and developing innovative therapies to treat serious diseases with unmet medical needs. Eukaryotic pathogens cause a range of infections in humans, animals, and plants. The impact of Eukaryotic Pathogens is vast, leading to debilitating diseases, crop damage, and economic losses.
Despite decades of relentless efforts, protozoan parasites such as Plasmodium, Toxoplasma, Babesia, Cryptosporidium, and Eimeria continue to pose a significant global health challenges. Our unwavering commitment lies in developing safe and potent drugs to combat effectively these intricate diseases.
Roundworms and flatworms, collectively known as helminths, present significant problem in the realm of parasitic infections, particularly due to emergence of drug resistance. In some areas, up to 98% of heartworm infected dogs are reported to be resistant to the available drugs.
Targeting the molecular infrastructure of Eukaryotic Pathogen
The microtubule cytoskeleton, a critical component in the intricate machinery of living organisms, plays a vital role in cell structure, division, transport, tissue development, and neuronal function. Proper microtubule structure and function is indispensable for any organism. At ASTRA Therapeutics, we have mastered the art of selectively targeting microtubules from Eukaryotic Pathogens.
Our Precision Lead Generator
"With our ParaX Platform, we have perfected the technology to exploit subtle sequence differences between tubulins from parasite pathogens and hosts to enable specific inhibitor design by precision atomic scale drug engineering. We call these species-specific parasite inhibitors: Parabulins ".
Precision-engineered drugs to fight specific Eukaryotic Pathogens.